Global Drug Discovery Informatics Market, By Function (Sequencing and Target Data Analysis, Docking, Molecular Modeling, Library and Database Preparation, and Others), Solutions (Software, and Services), Technique (Drug Discovery, and Drug Development), Mode (In-House Informatics, and Outsourced Informatics), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROS), and Others) – Industry Trends and Forecast to 2031.
Drug Discovery Informatics Market Analysis and Size
The drug discovery informatics market is witnessing significant advancement and growth fueled by the latest methods and technologies. Integration of AI, machine learning, and big data analytics revolutionizes research processes, enhancing efficiency and accuracy. This evolution empowers researchers to navigate vast datasets, accelerating drug discovery timelines and improving decision-making. As demand surges for innovative treatments, the market continues to expand, driving further innovation and investment.
The global drug discovery informatics market size was valued at USD 3.11 billion in 2023, is projected to reach USD 7.57 billion by 2031, with a CAGR of 11.77% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Function (Sequencing and Target Data Analysis, Docking, Molecular Modeling, Library and Database Preparation, and Others), Solutions (Software, and Services), Technique (Drug Discovery, and Drug Development), Mode (In-House Informatics, and Outsourced Informatics), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROS), and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Jubilant Biosys Ltd. (India), IBM (U.S.), Infosys Limited (India), Eurofins Scientific (Luxembourg), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer Inc. (U.S.), Schrödinger, Inc. (U.S.), Dassault Systèmes (France), Charles River Laboratories (U.S.), Selvita (Poland), Certara, USA (U.S.), Aragen Life Sciences Ltd. (India), Collaborative Drug Discovery Inc. (U.S.), OpenEye, Cadence Molecular Sciences (U.S.), Albany Molecular Research Inc. (U.S.), Accenture (Ireland), Cognizant (U.S.), Insilico Medicine (U.S.), and Boehringer Ingelheim International GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Drug discovery informatics is the application of computational methods and data analysis techniques to accelerate the process of discovering new medications. It involves the utilization of algorithms, machine learning, and big data analytics to predict drug-target interactions, optimize molecular structures, and streamline the drug development pipeline. By integrating diverse data sources, it aims to expedite the identification of promising drug candidates with enhanced efficacy and safety profiles.
Drug Discovery Informatics Market Dynamics
Drivers
- Advancements in Computational Biology and Bioinformatics
The integration of computational biology and bioinformatics tools accelerates drug discovery by enhancing the efficiency of analyzing biological data. For instance, sophisticated algorithms can predict protein structures and interactions, aiding in the identification of potential drug targets. This leads to the development of novel drugs with improved efficacy and safety profiles. As a result, the demand for drug discovery informatics solutions that leverage these advancements continues to grow, driving market expansion.
- Emergence of Big Data and AI
The emergence of Big Data and AI revolutionizes drug discovery, empowering researchers to analyze extensive biological and chemical datasets swiftly. AI-driven predictive modeling enhances virtual screening, expediting the identification of potential drug candidates. For instance, AI algorithms can analyze genomic data to predict drug responses in individual patients, facilitating the development of personalized medicine. This synergy of Big Data and AI drives the drug discovery informatics market by unlocking new efficiencies and possibilities.
Opportunities
- Increasing Adoption of Cloud Computing
The drug discovery informatics market is propelled by the increasing adoption of cloud computing. Cloud-based platforms provide scalability, flexibility, and cost-effectiveness, enabling researchers to access and analyze vast datasets globally. For instance, a pharmaceutical company utilizing cloud-based informatics can collaborate with researchers worldwide in real-time, accelerating drug discovery processes and fostering innovation. This accessibility and collaboration across geographies drive the market by enhancing efficiency and facilitating breakthrough discoveries.
- Rising Focus on Drug Repurposing and Virtual Screening
The surge in interest in drug repurposing and virtual screening, prompted by escalating costs and failure rates in conventional drug discovery, propels the demand for informatics solutions. These tools efficiently mine existing compound databases, identifying promising candidates and expediting virtual screening experiments. For instance, platforms like Schrödinger's Suite streamline molecular modeling and simulation, significantly enhancing drug discovery processes, and consequently driving growth in the informatics market.
Restraints/Challenges
- Privacy and Security Concerns
Privacy and security concerns surrounding sensitive patient data and proprietary information hinder the drug discovery informatics market. Compliance with regulations such as GDPR and HIPAA necessitates robust security measures, adding complexity and costs to implementation. Breaches or non-compliance can result in legal repercussions and damage trust within the industry, hampering market growth.
- Technical Expertise Requirement
The drug discovery informatics market faces hindrance due to the specialized technical expertise required for effective tool utilization, often lacking within research teams or organizations. This scarcity obstructs seamless integration and operation of informatics solutions, impeding progress and innovation in the field.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In February 2023, Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, achieved FDA Orphan Drug Designation for its AI-discovered drug targeting idiopathic pulmonary fibrosis, highlighting AI's potential in addressing unmet medical needs for rare diseases
- In February 2023, Evotec SE expanded its partnership with Related Sciences, extending their integrated multi-target drug discovery agreement to 2030. This collaboration harnesses Evotec's expertise across the drug development continuum, aiming to advance a diverse portfolio of drug candidates and drive innovation in the pharmaceutical industry
- In April 2022, Iktos, a leading provider of Artificial Intelligence solutions for new drug design, initiated a collaboration with Teijin Pharma Limited to advance AI technologies in small molecule drug discovery. This partnership underscores the growing interest in leveraging AI to accelerate drug development and enhance therapeutic outcomes
- In January 2022, Shanghai Fosun Pharmaceutical entered into a collaboration with Insilico Medicine to utilize AI technology in drug discovery and development. This strategic partnership signifies the increasing recognition of AI's potential to revolutionize pharmaceutical research and streamline the drug development process
Drug Discovery Informatics Market Scope
The market is segmented on the basis of function, solutions, technique, mode and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Function
- Sequencing and Target Data Analysis
- Docking
- Molecular Modeling
- Library and Database Preparation
- Others
Solutions
- Software
- Services
Technique
- Drug Discovery
- Identification, Validation, and Assay Development Informatics
- Lead Generation
- Enzymes
- Other Cleanings
- Drug Development
- Lead Optimization
- FHD Preparation
- Phase IA
- Phase IB/2
Mode
- In-House Informatics
- Outsourced Informatics
End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROS)
- Others
Drug Discovery Informatics Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, function, solutions, technique, mode and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to show a significant growth rate over the forecast period. This is attributed to the flourishing drug nanotechnology sector and ongoing research in software within the region, driving innovation and development across various industries.
North America is poised to lead the drug discovery informatics market, propelled by high incidences of infectious and oncology diseases. The region's robust growth in next-generation sequencing and chemical laboratories further bolsters its dominance, fostering innovation and advancement in pharmaceutical research and development.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Drug Discovery Informatics Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Jubilant Biosys Ltd. (India)
- IBM (U.S.)
- Infosys Limited (India)
- Eurofins Scientific (Luxembourg)
- Thermo Fisher Scientific Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Schrödinger, Inc. (U.S.)
- Dassault Systèmes (France)
- Charles River Laboratories (U.S.)
- Selvita (Poland)
- Certara, USA (U.S.)
- Aragen Life Sciences Ltd. (India)
- Collaborative Drug Discovery Inc. (U.S.)
- OpenEye, Cadence Molecular Sciences (U.S.)
- Albany Molecular Research Inc. (U.S.)
- Accenture (Ireland)
- Cognizant (U.S.)
- Insilico Medicine (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
SKU-